Daiichi Sankyo (OTCMKTS:DSNKY) Announces Earnings Results

Daiichi Sankyo (OTCMKTS:DSNKY) released its earnings results on Monday. The company reported $0.15 EPS for the quarter, Zacks reports. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. Daiichi Sankyo updated its FY 2026 guidance to 0.910-0.910 EPS.

Daiichi Sankyo Trading Up 3.3%

Shares of DSNKY stock opened at $17.05 on Tuesday. Daiichi Sankyo has a fifty-two week low of $15.56 and a fifty-two week high of $28.21. The stock has a market cap of $32.30 billion, a P/E ratio of 15.64, a P/E/G ratio of 0.85 and a beta of -0.25. The business has a fifty day simple moving average of $17.84 and a 200-day simple moving average of $20.32. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.